Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
about
FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP"Ziziphus jujuba": A red fruit with promising anticancer activitiesChemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastomaChemoresistance and targeted therapies in ovarian and endometrial cancersNon-invasive imaging of phosphoinositide-3-kinase-catalytic-subunit-alpha (PIK3CA) promoter modulation in small animal modelsUbiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancerA first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin.TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.Phytochemicals: a multitargeted approach to gynecologic cancer therapy.Cellular responses to Cisplatin-induced DNA damage.Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma.p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancersCell fate regulation by gelsolin in human gynecologic cancers.SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitroThe mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.Mitochondrial dysfunction impairs tumor suppressor p53 expression/function.Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cisOrmeloxifene efficiently inhibits ovarian cancer growth.P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and BakThe Flavonoid Apigenin Ameliorates Cisplatin-Induced Nephrotoxicity through Reduction of p53 Activation and Promotion of PI3K/Akt Pathway in Human Renal Proximal Tubular Epithelial Cells.CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathwayAlterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy.Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells.Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrumCOL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilizationMolecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinomaAKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers.PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation.Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fissionThe interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cellsThe AKT1/NF-kappaB/Notch1/PTEN axis has an important role in chemoresistance of gastric cancer cellsCrosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.New developments in the treatment of ovarian cancer--future perspectives.The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis.Molecular targeted therapy in ovarian cancer: what is on the horizon?FLIP: molecular switch between apoptosis and necroptosis.
P2860
Q26773368-04E0D4DA-9920-449C-AE11-D9DE6478BCEBQ26782533-3514A3DB-A61E-4A90-B527-B5D47632D07FQ26800007-87BB5CD5-0B37-4D3D-9836-D1A69A1B9EA9Q28073246-85D9DC38-6DD5-417A-AC3F-1052A06BB5C4Q28485978-DAF893E3-0601-4E76-A1D4-DAB67C91D4ADQ28674964-701F0D52-9E9F-4D2C-A732-42DBD5F5700AQ33426189-D44ACA2E-4C10-4F7C-9984-BFDC4A3586F8Q33688803-A74876F2-4B89-4C54-9276-CA808FF659D5Q33908881-D208897D-75EF-40F8-85D3-D111453E36C9Q34089685-598E686E-67B2-4239-871D-2A965DB22076Q34105105-65A61C94-68B1-40BD-B86D-337DF4C8FB8FQ34245099-6AEAE1B4-FB7F-4E61-BF08-6FE703FC5A7AQ34407454-6CC50BED-065C-4365-B6FE-68DCCC52ED36Q34566429-E0EC53F1-A9B8-451B-971E-C918BEBCDAC8Q35005636-D1A034C6-19B2-4838-A528-E55AA2E9715AQ35063355-A2A806FD-F807-4F44-80D5-F9593E1C82CEQ35084936-502A87E0-9576-492D-82AC-B70D4A4D1DFFQ35343857-35DDE7FF-3DDA-4A70-9501-7277F059A526Q35359342-62AA643A-2C01-44F5-8A0F-6635A7A8D0DFQ35541834-6834FF64-02F9-4BCB-9813-94D0F206461AQ35680762-B91E09B5-D8D8-411D-BFB6-88813EEA5434Q35803419-B9E8E5F3-4F71-41FF-B759-A85D594BA792Q35917703-D82B3777-6C28-4BFF-AA42-7DAC473C64DAQ36247462-4ECF7040-FDFB-47FC-8209-DC6454E7FC66Q36403630-B74E612B-86AC-4784-8190-A374256091CBQ36414284-DDD1BE53-6FBD-424B-8791-D6DDCF3D0B5FQ36511080-40F26584-ED6F-43C7-80C0-4BDF59FEA3D5Q36788196-1F75987D-98C1-4FDF-80AD-D7B333EAFE7EQ36794233-E69377E6-28EC-4AB7-A2D6-CF9EA1D1B975Q36832656-840E2E3C-1795-496D-A4B0-EDCBB4C96F18Q36891653-1334D58E-13AD-4997-ACE5-C0CB0A217CCBQ36951558-80DC884A-528C-40C7-9134-6AF91562276EQ37099682-BE4160A5-9DD1-46B0-BB58-C6C6383D663CQ37111154-ACF17B32-4F0F-4D47-AC72-2A72FC49D27EQ37299680-B9B47F6A-6DCC-4702-AFC4-03D5445376D1Q37317313-B165F7E8-1352-40F4-9E45-DA266CA56EB7Q37332487-29307E1B-5EAF-4509-82F8-5D1AE66AF0ACQ37488549-62A84555-9872-4A37-9E20-B465C4D50124Q37888659-95260F2B-73D6-4CBC-9BEC-E3EB663CCB6AQ38102627-255C72F8-3BFF-4E06-86C4-696CACACFAC6
P2860
Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Akt promotes chemoresistance i ...... FLICE-like inhibitory protein.
@en
Akt promotes chemoresistance i ...... FLICE-like inhibitory protein.
@nl
type
label
Akt promotes chemoresistance i ...... FLICE-like inhibitory protein.
@en
Akt promotes chemoresistance i ...... FLICE-like inhibitory protein.
@nl
prefLabel
Akt promotes chemoresistance i ...... FLICE-like inhibitory protein.
@en
Akt promotes chemoresistance i ...... FLICE-like inhibitory protein.
@nl
P2093
P2860
P356
P1433
P1476
Akt promotes chemoresistance i ...... FLICE-like inhibitory protein.
@en
P2093
P2860
P2888
P356
10.1038/ONC.2009.300
P407
P577
2009-10-05T00:00:00Z